Does Rallies show 13F holders for AXSM?

Yes. Rallies tracks hedge fund and 13F ownership data for AXSM, including fund names, share counts, latest tracked quarter, and position changes when available.

Is AXSM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AXSM. It does not provide personalized investment advice.

AXSM (Axsome Therapeutics, Inc) Stock Analysis - Hedge Fund Holdings

Axsome Therapeutics, Inc (AXSM) is a publicly traded Healthcare sector company. As of May 21, 2026, AXSM trades at $231.00 with a market cap of $11.70B and a P/E ratio of -61.59. AXSM moved +1.82% today. Year to date, AXSM is +34.48%; over the trailing twelve months it is +112.85%. Its 52-week range spans $75.56 to $235.92. Analyst consensus is strong buy with an average price target of $261.88. Rallies surfaces AXSM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns AXSM stock?

Hedge funds tracked by Rallies that own AXSM include Orbimed Advisors, Bridgewater Associates, Panagora Asset, Eisler Capital, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Axsome Therapeutics, Inc.

AXSM Key Metrics

Key financial metrics for AXSM
Metric	Value
Price	$231.00
Market Cap	$11.70B
P/E Ratio	-61.59
EPS	$-3.72
Dividend Yield	0.00%
52-Week High	$235.92
52-Week Low	$75.56
Volume	7
Avg Volume	0
Revenue (TTM)	$708.24M
Net Income	$-188.30M
Gross Margin	0.00%

Top Hedge Funds Holding AXSM

Orbimed Advisors holds 213.92K shares of AXSM, changed -15.49% as of Mar 31, 2026.
Bridgewater Associates holds 56.95K shares of AXSM, changed +20.04% as of Mar 31, 2026.
Panagora Asset holds 27.23K shares of AXSM, changed +0.00% as of Sep 30, 2024.
Eisler Capital holds 10.29K shares of AXSM, changed +13.70% as of Jun 30, 2024.
Farallon Capital holds 4.00K shares of AXSM, changed +0.00% as of Mar 31, 2026.

Latest AXSM News

Axsome jumps as Q1 sales surge 57% and AUVELITY Alzheimer’s approval boosts outlook — May 5, 2026
Guggenheim Lifts Axsome Therapeutics Price Target to $260 After 57% Q1 Revenue Surge — May 4, 2026
Axsome jumps as Q1 revenue surges 57% and Alzheimer’s launch plans firm up — May 4, 2026
Axsome’s Q1 Revenue Soars 57% to $191.2M, FDA Approves Auvelity — May 4, 2026
Axsome slides as traders lock in gains after FDA win, ahead of May 4 earnings — May 1, 2026

Recent AXSM Insider Trades

Jacobson Mark L. sold 233 (~$53.17K) on May 5, 2026.
Jacobson Mark L. sold 4.52K (~$1.03M) on May 4, 2026.
Maizel Ari sold 7.50K (~$1.37M) on Apr 22, 2026.

AXSM Analyst Consensus

19 analysts cover AXSM: 0 strong buy, 18 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $261.88.

Common questions about AXSM

Who owns AXSM stock?: Hedge funds tracked by Rallies that own AXSM include Orbimed Advisors, Bridgewater Associates, Panagora Asset, Eisler Capital, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Axsome Therapeutics, Inc.
Does Rallies show 13F holders for AXSM?: Yes. Rallies tracks hedge fund and 13F ownership data for AXSM, including fund names, share counts, latest tracked quarter, and position changes when available.
Is AXSM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AXSM. It does not provide personalized investment advice.